R. 1. Lee, H. Song, I. Friedrich, M. Gauliard, A. Detert et al., Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists

A. Moustou, A. Matekovits, C. Dessinioti, C. Antoniou, P. Sfikakis et al., Cutaneous side effects of anti???tumor necrosis factor biologic therapy: A clinical review, Journal of the American Academy of Dermatology, vol.61, issue.3, pp.486-504, 2009.
DOI : 10.1016/j.jaad.2008.10.060

M. Flendrie, W. Vissers, M. Creemers, E. De-jong, P. Van-de-kerkhof et al., Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study, Arthritis Research & Therapy, vol.7, issue.3, pp.666-676, 2005.
DOI : 10.1186/ar1724

N. Bonnet, S. Guis, M. Koeppel, J. Roudier, J. Grimaud et al., ??v??nements cutan??omuqueux au cours des traitements par anti-TNF alpha??: ??tude observationnelle prospective de 41??cas, Annales de Dermatologie et de V??n??r??ologie, vol.137, issue.1, pp.12-20, 2010.
DOI : 10.1016/j.annder.2009.12.003

D. Lebas, D. Staumont-sallé, E. Solau-gervais, R. Flipo, and E. Delaporte, Manifestations cutan??es observ??es au cours d???un traitement par anti-TNF alpha : 11 observations, Annales de Dermatologie et de V??n??r??ologie, vol.134, issue.4, pp.337-379, 2007.
DOI : 10.1016/S0151-9638(07)89187-3

M. Viguier, P. Richette, H. Bachelez, D. Wendling, and F. Aubin, Manifestations cutanées paradoxales des anti-TNF-alpha. Annales de Dermatologie et de Vénéréologie, pp.64-71, 2010.
DOI : 10.1016/j.annder.2009.10.004

W. Amari, A. Zeringue, J. Mcdonald, L. Caplan, S. Eisen et al., Risk of nonmelanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) 2011 août, pp.1431-1440

E. Chakravarty, K. Michaud, and F. Wolfe, Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors, J. Rheumatol, vol.32, issue.11, pp.2130-2135, 2005.

A. Collamer, K. Guerrero, J. Henning, and D. Battafarano, Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action, Arthritis & Rheumatism, vol.44, issue.7
DOI : 10.1002/art.23835

J. Ko, A. Gottlieb, and J. Kerbleski, Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases, Journal of Dermatological Treatment, vol.174, issue.15, pp.100-108, 2009.
DOI : 10.1016/S0140-6736(02)08512-4

U. Wollina, G. Hansel, A. Koch, J. Schönlebe, E. Köstler et al., Tumor Necrosis Factor-?? Inhibitor-Induced Psoriasis or Psoriasiform Exanthemata, American Journal of Clinical Dermatology, vol.56, issue.1, pp.1-14, 2008.
DOI : 10.2165/00128071-200809010-00001

J. Kerbleski and A. Gottlieb, Dermatological complications and safety of anti-TNF treatments, Gut, vol.58, issue.8
DOI : 10.1136/gut.2008.163683

D. Furst, The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis, Seminars in Arthritis and Rheumatism, vol.39, issue.5
DOI : 10.1016/j.semarthrit.2008.10.002

M. Doran, C. Crowson, G. Pond, O. Fallon, W. Gabriel et al., Predictors of infection in rheumatoid arthritis Arthritis Rheum Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate, Ann. Rheum. Dis, vol.4653, issue.94, pp.2294-300, 1994.

A. Strangfeld, J. Listing, P. Herzer, A. Liebhaber, K. Rockwitz et al., Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents, JAMA. févr, vol.18301, issue.7, pp.737-781, 2009.

C. Salliot, M. Dougados, and L. Gossec, Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials, Annals of the Rheumatic Diseases, vol.68, issue.1
DOI : 10.1136/ard.2007.083188

M. Khraishi, A. Russell, and W. Olszynski, Safety profile of abatacept in rheumatoid arthritis: A review, Clinical Therapeutics, vol.32, issue.11, pp.1855-70, 2010.
DOI : 10.1016/j.clinthera.2010.10.011

M. Schiff, Abatacept treatment for rheumatoid arthritis Rheumatology (Oxford) 2011 mars, pp.437-486

O. Goldzweig and P. Hashkes, Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy, Drug Des Devel Ther, vol.5, pp.61-70, 2011.

A. Mohrbacher, B cell non-Hodgkin's lymphoma: rituximab safety experience, Arthritis Res

. Ducasse, T. Vo-de-la, J. Pintado, M. Gordon, and M. Oyonarte, Lesiones cut??neas en una paciente con linfoma no Hodgkin, Enfermedades Infecciosas y Microbiolog??a Cl??nica, vol.25, issue.7, pp.489-90, 2007.
DOI : 10.1157/13108713

D. Selleslag, A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B, Acta Biomed, vol.77, issue.2, pp.32-37, 2006.

F. Wolfe and K. Michaud, Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study, Arthritis & Rheumatism, vol.92, issue.9, pp.2886-95, 2007.
DOI : 10.1002/art.22864

T. Bongartz, A. Sutton, M. Sweeting, I. Buchan, E. Matteson et al., Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies, JAMA, vol.295, issue.19, pp.2275-85, 2006.
DOI : 10.1001/jama.295.19.2275

J. Askling, Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Annals of the Rheumatic Diseases, pp.1421-1427, 2005.

K. Saag, G. Teng, N. Patkar, J. Anuntiyo, C. Finney et al., American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis, Arthritis & Rheumatism, vol.21, issue.2, pp.762-84, 2008.
DOI : 10.1002/art.23721

T. Ding, J. Ledingham, R. Luqmani, S. Westlake, K. Hyrich et al., BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies, Rheumatology, vol.49, issue.11, pp.2217-2226, 2010.
DOI : 10.1093/rheumatology/keq249a

E. Chakravarty and E. Farmer, Risk of skin cancer in the drug treatment of rheumatoid arthritis, Expert Opinion on Drug Safety, vol.32, issue.5
DOI : 10.1002/ajh.21003

P. Guyot-caquelin, L. Geoffrois, A. Barbaud, P. Trechot, J. Schmutz et al., Evaluation of information about prophylactic treatment and management of hand-foot reactions caused by antiangiogenic therapies], Ann Dermatol Venereol, vol.138, pp.8-9565, 2011.

F. Nestle, D. Meglio, P. Qin, J. Nickoloff, and B. , Skin immune sentinels in health and disease, Nature Reviews Immunology, vol.182
DOI : 10.1038/nri2622

M. Doutre and . Le-système-immunitaire-cutané, Annales de Dermatologie et de Vénéréologie, pp.257-262, 2009.

P. Elias, The skin barrier as an innate immune element, Seminars in Immunopathology, vol.11, issue.Pt 3, pp.3-14, 2007.
DOI : 10.1007/s00281-007-0060-9

R. Medzhitov, C. Janeway, and . Jr, Innate immunity, Current Opinion in Immunology, vol.15, issue.1, pp.338-382, 2000.
DOI : 10.1016/S0952-7915(02)00019-5

URL : https://hal.archives-ouvertes.fr/hal-01438527

A. Iwasaki and R. Medzhitov, Regulation of Adaptive Immunity by the Innate Immune System, Science, vol.327, issue.5963
DOI : 10.1126/science.1183021

P. Delves and I. Roitt, The immune system. First of two parts, N. Engl. J. Med. 2000 juill, vol.6343, issue.1, pp.37-49

J. Parkin and B. Cohen, An overview of the immune system, The Lancet, vol.357, issue.9270, pp.1777-89, 2001.
DOI : 10.1016/S0140-6736(00)04904-7

L. Miller, Toll-Like Receptors in Skin, Advances in Dermatology, vol.24, pp.71-87, 2008.
DOI : 10.1016/j.yadr.2008.09.004

K. Takeda and S. Akira, Toll-like receptors in innate immunity. International Immunology, 2005.

M. Schiller, D. Metze, T. Luger, S. Grabbe, and M. Gunzer, Immune response modifiers ? mode of action, Experimental Dermatology, vol.21, issue.5, pp.331-372, 2006.
DOI : 10.1023/B:APPT.0000025805.55340.c3

L. Miller and R. Modlin, Toll-like receptors in the skin Delves PJ, Roitt IM. The immune system. Second of two parts, Semin Immunopathol. N. Engl. J. Med, vol.29343, issue.12, pp.15-26, 2000.

G. Dunn, A. Bruce, H. Ikeda, L. Old, and R. Schreiber, Cancer immunoediting: from immunosurveillance to tumor escape, Nature Immunology, vol.3, issue.11, pp.991-999, 2002.
DOI : 10.1038/ni1102-991

N. Bhardwaj, Harnessing the immune system to treat cancer, Journal of Clinical Investigation, vol.117, issue.5, pp.1130-1136, 2007.
DOI : 10.1172/JCI32136

M. Vesely, M. Kershaw, R. Schreiber, and M. Smyth, Natural Innate and Adaptive Immunity to Cancer, Annual Review of Immunology, vol.29, issue.1, pp.235-71, 2011.
DOI : 10.1146/annurev-immunol-031210-101324

J. Valladeau and S. Saeland, Cutaneous dendritic cells, Seminars in Immunology, vol.17, issue.4, pp.273-83, 2005.
DOI : 10.1016/j.smim.2005.05.009

M. Merad, F. Ginhoux, and C. M. , Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells, Nature Reviews Immunology, vol.103, issue.12, pp.935-982, 2008.
DOI : 10.1038/nri2455

B. Reizis, A. Bunin, H. Ghosh, K. Lewis, and V. Sisirak, Plasmacytoid Dendritic Cells: Recent Progress and Open Questions, Annual Review of Immunology, vol.29, issue.1, pp.163-83, 2011.
DOI : 10.1146/annurev-immunol-031210-101345

M. Staquet, N. Piccardi, P. Msika, and D. Schmitt, Langerhans cell migration. An essential step in the induction of contact hypersensitivity], Ann Dermatol Venereol, vol.129, pp.8-91071, 2002.

S. Grabbe, K. Steinbrink, M. Steinert, T. Luger, and T. Schwarz, Removal of the majority of epidermal Langerhans cells by topical or systemic steroid application enhances the effector phase of murine contact hypersensitivity, J. Immunol, vol.155, issue.9, pp.4207-4224, 1995.

D. Kaplan, A. Kissenpfennig, and B. Clausen, Insights into Langerhans cell function from Langerhans cell ablation models, European Journal of Immunology, vol.204, issue.9, pp.2369-76, 2008.
DOI : 10.1002/eji.200838397

B. Davis, H. Wen, and J. Ting, The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases, Annual Review of Immunology, vol.29, issue.1, pp.707-742, 2011.
DOI : 10.1146/annurev-immunol-031210-101405

J. Schröder and J. Harder, Innate antimicrobial peptides in the skin, Med Sci, vol.22, issue.2, pp.153-160, 2006.

M. Bhushan, M. Cumberbatch, R. Dearman, S. Andrew, I. Kimber et al., Tumour necrosis factor-??-induced migration of human Langerhans cells: the influence of ageing, British Journal of Dermatology, vol.94, issue.Suppl. 35, pp.32-40, 2002.
DOI : 10.1046/j.1365-2133.2002.04549.x

A. Black, M. Ardern-jones, V. Kasprowicz, P. Bowness, L. Jones et al., Human keratinocyte induction of rapid effector function in antigen-specific memory CD4+ and CD8+ T cells, European Journal of Immunology, vol.274, issue.6
DOI : 10.1002/eji.200636915

D. Cua and C. Tato, Innate IL-17-producing cells: the sentinels of the immune system, Nature Reviews Immunology, vol.31, issue.7, pp.479-89, 2010.
DOI : 10.1038/nri2800

A. Asarch, O. Barak, D. Loo, and A. Gottlieb, Th17 cells: A new paradigm for cutaneous inflammation, Journal of Dermatological Treatment, vol.174, issue.5, pp.259-66, 2008.
DOI : 10.1080/09546630802206686

K. Papp, R. Langley, M. Lebwohl, G. Krueger, P. Szapary et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), The Lancet, vol.371, issue.9625, 2008.
DOI : 10.1016/S0140-6736(08)60726-6

K. Loser and S. Beissert, Dendritic Cells and T Cells in the Regulation of Cutaneous Immunity, Advances in Dermatology, vol.23, pp.307-340, 2007.
DOI : 10.1016/j.yadr.2007.07.014

S. Sakaguchi, M. Miyara, C. Costantino, and D. Hafler, FOXP3+ regulatory T cells in the human immune system, Nature Reviews Immunology, vol.34, issue.7, pp.490-500, 2010.
DOI : 10.1038/nri2785

S. Sakaguchi, Regulatory T cells ??? a brief history and perspective, European Journal of Immunology, vol.25, issue.S1, pp.3-17, 2011.
DOI : 10.1002/eji.200737593

S. Beetz, D. Wesch, L. Marischen, S. Welte, H. Oberg et al., Innate immune functions of human ???? T cells, Immunobiology, vol.213, issue.3-4, pp.3-4173, 2008.
DOI : 10.1016/j.imbio.2007.10.006

M. Bonneville, O. Brien, R. Born, and W. , ???? T cell effector functions: a blend of innate programming and acquired plasticity, Nature Reviews Immunology, vol.18, issue.7, pp.467-78, 2010.
DOI : 10.1038/nri2781

M. Metz, F. Siebenhaar, and M. Maurer, Mast cell functions in the innate skin immune system, Immunobiology, vol.213, issue.3-4
DOI : 10.1016/j.imbio.2007.10.017

J. Marshall, Mast-cell responses to pathogens, Nature Reviews Immunology, vol.63, issue.10, pp.787-99, 2004.
DOI : 10.1084/jem.192.12.1849

T. Schwarz and . Photoimmunosuppression, Photoimmunosuppression, Photodermatology, Photoimmunology & Photomedicine, vol.276, issue.3, pp.141-146, 2002.
DOI : 10.1034/j.1600-0781.2002.180307.x

F. Aubin, Mechanisms involved in ultraviolet light-induced immunosuppression, Eur J Dermatol, vol.13, issue.6, pp.515-538, 2003.

S. Seité, H. Zucchi, D. Moyal, S. Tison, D. Compan et al., Alterations in human epidermal Langerhans cells by ultraviolet radiation: quantitative and morphological study, British Journal of Dermatology, vol.3, issue.2, pp.291-300, 2003.
DOI : 10.1046/j.1365-2133.1996.d01-732.x

M. Grewe, Chronological ageing and photoageing of dendritic cells, Clinical and Experimental Dermatology, vol.106, issue.7, pp.608-620, 2001.
DOI : 10.1016/S0923-1811(99)00076-6

K. Loser and S. Beissert, Regulation of cutaneous immunity by the environment: An important role for UV irradiation and vitamin D, International Immunopharmacology, vol.9, issue.5, pp.587-596, 2009.
DOI : 10.1016/j.intimp.2009.01.024

S. Ullrich and D. Schmitt, The role of cytokines in UV-induced systemic immune suppression, Journal of Dermatological Science, vol.23
DOI : 10.1016/S0923-1811(99)00073-0

W. Lewis, E. Simanyi, H. Li, C. Thompson, T. Nasti et al., Regulation of ultraviolet radiation induced cutaneous photoimmunosuppression by Toll-like receptor-4, Archives of Biochemistry and Biophysics, vol.508, issue.2, pp.171-178, 2011.
DOI : 10.1016/j.abb.2011.01.005

U. Photothérapie, P. Gläser, R. Navid, F. Schuller, W. Jantschitsch et al., Thérapeutique Dermatologique Médecine Science Flammarion. 48 UV-B radiation induces the expression of antimicrobial peptides in human keratinocytes in vitro and in vivo, J

F. Aubin, O. Humbey, J. Guérrini, C. Mougin, and R. Laurent, Non-melanoma skin cancers and human papillomavirus], Ann Dermatol Venereol, vol.13012, issue.1, pp.1131-1139, 2003.

K. Biliris, E. Koumantakis, D. Dokianakis, G. Sourvinos, and D. Spandidos, Human papillomavirus infection of non-melanoma skin cancers in immunocompetent hosts. Cancer Letters, pp.83-91, 2000.

S. Mouret, A. Favier, J. Beani, and M. Leccia, Differential p53-mediated responses to solar-simulated radiation in human papillomavirus type 16-infected keratinocytes, Experimental Dermatology, vol.21, issue.6, pp.476-84, 2007.
DOI : 10.1093/emboj/18.5.1223

Q. Zhou, K. Zhu, and H. Cheng, Ubiquitination in host immune response to human papillomavirus infection, Archives of Dermatological Research, vol.47, issue.7, pp.217-247, 2011.
DOI : 10.1007/s00403-011-1141-0

I. Frazer, R. Thomas, J. Zhou, G. Leggatt, L. Dunn et al., Potential strategies utilised by papillomavirus to evade host immunity 54. O'Brien PM, Saveria Campo M. Evasion of host immunity directed by papillomavirusencoded proteins, Immunol. Rev. Virus Res, vol.16888, issue.12, pp.131-42103, 1999.

C. Gomez, V. Nomellini, D. Faunce, and E. Kovacs, Innate immunity and aging, Experimental Gerontology, vol.43, issue.8, pp.718-746, 2008.
DOI : 10.1016/j.exger.2008.05.016

C. Sunderkötter, H. Kalden, and T. Luger, Aging and the Skin Immune System, Archives of Dermatology, vol.133, issue.10, pp.1256-62, 1997.
DOI : 10.1001/archderm.1997.03890460078009

J. Thivolet and J. Nicolas, Skin ageing and immune competence, British Journal of Dermatology, vol.92, issue.s35, 1990.
DOI : 10.1007/BF00412884

M. Yaar and B. Gilchrest, Ageing and photoageing of keratinocytes and melanocytes, Clinical and Experimental Dermatology, vol.10, issue.7
DOI : 10.1073/pnas.180320897

U. Hengge and T. Ruzicka, Topical Immunomodulation in Dermatology, Dermatologic Surgery, vol.30, issue.8, pp.1101-1113, 2004.
DOI : 10.1097/00042728-200408000-00008

D. Sauder, Mechanism of Action and Emerging Role of Immune Response Modifier Therapy in Dermatologic Conditions, Journal of Cutaneous Medicine & Surgery, vol.134, issue.suppl, pp.3-12, 2004.
DOI : 10.1007/s10227-004-0803-3

N. Novak, C. Yu, T. Bieber, and J. Allam, Toll-like receptor 7 agonists and skin. Drug News Perspect, pp.158-65, 2008.

D. Bilu, D. Sauder, A. Hennino, and J. Nicolas, Imiquimod: modes of actionTNF alpha in the physiopathology of psoriasis], Br. J. Dermatol. Ann Dermatol Venereol, vol.149133, issue.2, pp.174-80, 2003.

P. Szlosarek and F. Balkwill, Tumour necrosis factor ??: a potential target for the therapy of solid tumours, The Lancet Oncology, vol.4, issue.9, pp.565-73, 2003.
DOI : 10.1016/S1470-2045(03)01196-3

F. Balkwill, Tumour necrosis factor and cancer, Nature Reviews Cancer, vol.265, issue.5, pp.361-71, 2009.
DOI : 10.1038/nature01322

M. Khraishi, Comparative Overview of Safety of the Biologics in Rheumatoid Arthritis. The Journal of Rheumatology Supplement, pp.25-32, 2009.

W. Dixon, K. Watson, M. Lunt, and K. Hyrich, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al. Rates of serious infection, including sitespecific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti?tumor necrosis factor therapy

M. Gardam, E. Keystone, R. Menzies, S. Manners, E. Skamene et al., Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management, The Lancet Infectious Diseases, vol.3, issue.3, pp.148-55, 2003.
DOI : 10.1016/S1473-3099(03)00545-0

F. Balkwill and C. Joffroy, TNF: a tumor-suppressing factor or a tumor-promoting factor? Future Oncol, pp.1833-1839, 2010.

P. Fan and K. Leong, The use of biological agents in the treatment of rheumatoid arthritis

M. Wong, D. Ziring, Y. Korin, S. Desai, S. Kim et al., TNF?? blockade in human diseases: Mechanisms and future directions, Clinical Immunology, vol.126, issue.2, pp.121-157, 2008.
DOI : 10.1016/j.clim.2007.08.013

G. Silverman and D. Carson, Roles of B cells in rheumatoid arthritis, Arthritis Research & Therapy, vol.5, issue.Suppl 4, pp.1-6, 2003.
DOI : 10.1186/ar1010

D. Jones and D. Jones, Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis RéfleXions Rhumatologiques: Blocage de l'IL-6, CMAMD. 2010 déc, vol.193, pp.81-90, 2009.

O. Goldzweig and P. Hashkes, Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy, Drug Des Devel Ther, vol.5, pp.61-70

M. Genovese, J. Becker, M. Schiff, M. Luggen, Y. Sherrer et al., Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor ?? Inhibition, New England Journal of Medicine, vol.353, issue.11, pp.1114-1137, 2005.
DOI : 10.1056/NEJMoa050524

K. Saag, G. Teng, N. Patkar, J. Anuntiyo, C. Finney et al., American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis, Arthritis & Rheumatism, vol.21, issue.2, pp.762-84, 2008.
DOI : 10.1002/art.23721

T. Pham, B. Fautrel, E. Dernis, P. Goupille, F. Guillemin et al., Recommendations of the French Society for Rheumatology regarding TNF?? antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update, Joint Bone Spine, vol.74, issue.6, pp.638-684, 2007.
DOI : 10.1016/j.jbspin.2007.10.003

M. Rudwaleit and W. Taylor, Classification criteria for psoriatic arthritis and ankylosing spondylitis/axial spondyloarthritis. Best Practice & Research Clinical Rheumatology, pp.589-604, 2010.

J. Lin, D. Ziring, S. Desai, S. Kim, M. Wong et al., TNF? blockade in human diseases: An overview of efficacy and safety. Clinical Immunology 88. CRI. Fiches pratiques. Utilisation du Tocilizumab dans les spondylarthrites Classification criteria for psoriatic arthritis: Development of new criteria from a large international study, Revue du Rhumatisme Arthritis Rheum, vol.12654, issue.768, pp.13-302665, 2006.

S. Kyle, Guideline for anti-TNF-?? therapy in psoriatic arthritis, Rheumatology, vol.44, issue.3, pp.390-397, 2005.
DOI : 10.1093/rheumatology/keh514

A. Sharma and S. Dogra, Management of psoriatic arthritis, Indian Journal of Dermatology, Venereology, and Leprology, vol.76, issue.6, pp.645-51, 2010.
DOI : 10.4103/0378-6323.72457

N. Ruperto, D. Lovell, P. Quartier, E. Paz, N. Rubio-pérez et al., Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial CRI. Fiches pratiques. Utilisation des anti-TNF?: autres indications, Lancet. Revue du rhumatisme, vol.37277, issue.9636, pp.383-91, 2007.

M. Doran, C. Crowson, G. Pond, O. Fallon, W. Gabriel et al., Predictors of infection in rheumatoid arthritis, Arthritis & Rheumatism, vol.140, issue.9, pp.2294-300, 2002.
DOI : 10.1002/art.10529

J. Franklin, M. Lunt, D. Bunn, D. Symmons, and A. Silman, Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis, Annals of the Rheumatic Diseases, vol.66, issue.3
DOI : 10.1136/ard.2006.057265

J. Cosnes, M. Karagas, G. Cushing, . Jr, E. Greenberg et al., Traitements immunosuppresseurs chez les patients à risque. 2007. 100 Nonmelanoma skin cancers and glucocorticoid therapy, Br. J. Cancer, vol.85, issue.5, pp.683-689, 2001.

H. Sørensen, L. Mellemkjaer, G. Nielsen, J. Baron, J. Olsen et al., Skin Cancers and Non-Hodgkin Lymphoma Among Users of Systemic Glucocorticoids: A Population-Based Cohort Study, JNCI Journal of the National Cancer Institute, vol.96, issue.9, pp.709-720, 2004.
DOI : 10.1093/jnci/djh118

A. Jensen, H. Thomsen, M. Engebjerg, A. Olesen, S. Friis et al., Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case???control study, British Journal of Cancer, vol.58, issue.1, pp.200-205, 2009.
DOI : 10.1136/bmj.39507.551644.BE

M. Krathen, A. Gottlieb, and P. Mease, Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis, The Journal of Rheumatology, vol.37, issue.11, pp.2205-2220, 2010.
DOI : 10.3899/jrheum.100041

E. Chakravarty, K. Michaud, and F. Wolfe, Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors, J. Rheumatol, vol.32, issue.11, pp.2130-2135, 2005.

V. Mehta, S. Kisalay, C. Balachandran, and . Leflunomide, Leflunomide, Indian Journal of Dermatology, Venereology and Leprology, vol.75, issue.4, pp.422-426, 2009.
DOI : 10.4103/0378-6323.53157

R. Brem and P. Karran, Multiple forms of DNA Damage Caused by UVA Photoactivation of DNA 6-Thioguanine, Photochemistry and Photobiology, vol.30, issue.1, pp.5-13, 2012.
DOI : 10.1111/j.1751-1097.2011.01043.x

M. Setshedi, D. Epstein, T. Winter, L. Myer, G. Watermeyer et al., Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: A cohort study, Journal of Gastroenterology and Hepatology, vol.22, issue.80, pp.385-394, 2012.
DOI : 10.1111/j.1440-1746.2011.06865.x

A. Moustou, A. Matekovits, C. Dessinioti, C. Antoniou, P. Sfikakis et al., Cutaneous side effects of anti???tumor necrosis factor biologic therapy: A clinical review, Journal of the American Academy of Dermatology, vol.61, issue.3, pp.486-504, 2009.
DOI : 10.1016/j.jaad.2008.10.060

M. Flendrie, W. Vissers, M. Creemers, E. De-jong, P. Van-de-kerkhof et al., Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study, Arthritis Research & Therapy, vol.7, issue.3, pp.666-676, 2005.
DOI : 10.1186/ar1724

H. Lee, I. Song, M. Friedrich, A. Gauliard, J. Detert et al., Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists

J. Askling, Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Annals of the Rheumatic Diseases, pp.1421-1427, 2005.

D. Margolis, W. Bilker, S. Hennessy, C. Vittorio, J. Santanna et al., The risk of malignancy associated with psoriasis, Arch Dermatol, vol.137, issue.6, pp.778-83, 2001.

I. Marcil and R. Stern, Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study, The Lancet, vol.358, issue.9287, pp.1042-1047, 2001.
DOI : 10.1016/S0140-6736(01)06179-7

L. Naldi, Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies, Clinics in Dermatology, vol.28, issue.1, pp.88-92, 2010.
DOI : 10.1016/j.clindermatol.2009.03.003

C. Paul, V. Ho, C. Mcgeown, E. Christophers, B. Schmidtmann et al., Risk of Malignancies in Psoriasis Patients Treated with Cyclosporine: a 5 y Cohort Study, Journal of Investigative Dermatology, vol.120, issue.2, pp.211-217, 2003.
DOI : 10.1046/j.1523-1747.2003.12040.x

R. Patel, L. Clark, M. Lebwohl, and J. Weinberg, Treatments for psoriasis and the risk of malignancy, Journal of the American Academy of Dermatology, vol.60, issue.6, pp.1001-1018, 2009.
DOI : 10.1016/j.jaad.2008.12.031

M. Raiss, I. Templier, and J. Beani, PUVAth??rapie et cancers cutan??s, Annales de Dermatologie et de V??n??r??ologie, vol.131, issue.5, pp.437-480, 2004.
DOI : 10.1016/S0151-9638(04)93636-8

R. Stern and E. Lunder, Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV- A radiation (PUVA) A meta-analysis, Arch Dermatol, vol.134, issue.12, pp.1582-1587, 1998.

N. Larmonier, D. Cathelin, C. Larmonier, A. Nicolas, D. Merino et al., The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor ? receptor IgG1-Fc fusion complex therapy, Exp. Cell Res. Journal of the American Academy of Dermatology, vol.31345, issue.1216, pp.2345-55953, 2001.

K. Saag, G. Teng, N. Patkar, J. Anuntiyo, C. Finney et al., American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis, Arthritis & Rheumatism, vol.21, issue.2, pp.762-84, 2008.
DOI : 10.1002/art.23721

T. Ding, J. Ledingham, R. Luqmani, S. Westlake, K. Hyrich et al., BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies, Rheumatology, vol.49, issue.11, pp.2217-2226, 2010.
DOI : 10.1093/rheumatology/keq249a

F. Wolfe and K. Michaud, Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study, Arthritis & Rheumatism, vol.92, issue.9, pp.2886-95, 2007.
DOI : 10.1002/art.22864

E. Chakravarty and E. Farmer, Risk of skin cancer in the drug treatment of rheumatoid arthritis, Expert Opinion on Drug Safety, vol.32, issue.5
DOI : 10.1002/ajh.21003

J. Kerbleski and A. Gottlieb, Dermatological complications and safety of anti-TNF treatments, Gut, vol.58, issue.8
DOI : 10.1136/gut.2008.163683

T. Bongartz, A. Sutton, M. Sweeting, I. Buchan, E. Matteson et al., Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies, JAMA, vol.295, issue.19, pp.2275-85, 2006.
DOI : 10.1001/jama.295.19.2275

A. Esser, A. Abril, S. Fayne, and J. Doyle, Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab, Journal of the American Academy of Dermatology, vol.50, issue.5, 2004.
DOI : 10.1016/j.jaad.2003.11.044

. Amari, Non-melanoma and melanoma skin cancer risk in a national cohort of veterans with RA, 2009.

S. Setoguchi, D. Solomon, M. Weinblatt, J. Katz, J. Avorn et al., Tumor necrosis factor ?? antagonist use and cancer in patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.14, issue.9, pp.2757-64, 2006.
DOI : 10.1002/art.22056

W. Dixon, K. Watson, M. Lunt, and L. Mercer, Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register, Arthritis Care & Research, vol.56, issue.Suppl 2, pp.755-63, 2010.
DOI : 10.1002/acr.20129

M. Lebwohl, R. Blum, E. Berkowitz, D. Kim, R. Zitnik et al., No Evidence for Increased Risk of Cutaneous Squamous Cell Carcinoma in Patients With Rheumatoid Arthritis Receiving Etanercept for Up to 5 Years, Archives of Dermatology, vol.141, issue.7, pp.861-865, 2005.
DOI : 10.1001/archderm.141.7.861

T. Bongartz, F. Warren, D. Mines, E. Matteson, K. Abrams et al., Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials, Annals of the Rheumatic Diseases, vol.68, issue.7, pp.1177-83, 2009.
DOI : 10.1136/ard.2008.094904

J. Leombruno, T. Einarson, and E. Keystone, The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events, Annals of the Rheumatic Diseases, vol.68, issue.7, pp.1136-1181, 2009.
DOI : 10.1136/ard.2008.091025

C. Nannini, F. Cantini, L. Niccoli, E. Cassarà, C. Salvarani et al., Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum, pp.801-813, 2009.

S. Engel, T. Hullar, D. Adkins, W. Thorstad, and J. Sunwoo, Temporal Relationship Between Antitumor Necrosis Factor-?? Antibody Therapy and Recrudescence of Head and Neck Squamous Cell Carcinoma, The Laryngoscope, vol.13, issue.3, pp.450-452, 2008.
DOI : 10.1097/MLG.0b013e31815abf4c

J. Askling, R. Van-vollenhoven, F. Granath, P. Raaschou, C. Fored et al., Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum, pp.3180-3189, 2009.

T. Sokka, B. Abelson, and P. T. , Mortality in rheumatoid arthritis, update, 2008.

S. Bernatsky, Y. Habel, E. Rahme, A. Van-der-heide, A. Kruize et al., Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate, J. Rheumatol. Ann. Rheum. Dis, vol.3753, issue.54, pp.928-31224, 1994.

E. Keystone, Does Anti-Tumor Necrosis Factor-{alpha} Therapy Affect Risk of Serious Infection and Cancer in Patients with Rheumatoid Arthritis?: A Review of Longterm Data, J Rheumatol

D. Furst, The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis, Seminars in Arthritis and Rheumatism, vol.39, issue.5
DOI : 10.1016/j.semarthrit.2008.10.002

J. Listing, A. Strangfeld, S. Kary, R. Rau, U. Von-hinueber et al., Infections in patients with rheumatoid arthritis treated with biologic agents, Arthritis & Rheumatism, vol.47, issue.11, pp.3403-3415, 2005.
DOI : 10.1002/art.21386

A. Mufti, B. Toye, R. Mckendry, and J. Angel, Mycobacterium abscessus infection after use of tumor necrosis factor ?? inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor ?? inhibitor use, Diagnostic Microbiology and Infectious Disease, vol.53, issue.3, pp.233-241, 2005.
DOI : 10.1016/j.diagmicrobio.2005.06.006

V. Katikireddi, S. Whittle, and C. Hill, Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis, International Journal of Rheumatic Diseases, vol.9, issue.Suppl. 2, pp.12-26, 2010.
DOI : 10.1111/j.1756-185X.2009.01457.x

C. Salliot, L. Gossec, A. Ruyssen-witrand, M. Luc, M. Duclos et al., Infections during tumour necrosis factor-?? blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients, Rheumatology, vol.46, issue.2, pp.327-361, 2007.
DOI : 10.1093/rheumatology/kel236

S. Kim and D. Solomon, Tumor necrosis factor blockade and the risk of viral infection, Nature Reviews Rheumatology, vol.43, issue.3, pp.165-74, 2010.
DOI : 10.1038/nrrheum.2009.279

A. Strangfeld, J. Listing, P. Herzer, A. Liebhaber, K. Rockwitz et al., Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents, JAMA. févr, vol.18301, issue.7, pp.737-781, 2009.

N. Balato, F. Gaudiello, A. Balato, F. Ayala, S. Guis et al., Development of primary varicella infection during infliximab treatment for psoriasis, Journal of the American Academy of Dermatology, vol.60, issue.4, 2009.
DOI : 10.1016/j.jaad.2008.10.002

E. Adenis-lamarre, E. Kostrzewa, J. Texier-maugein, and M. Doutre, Infection cutanée à Mycobacterium chelonae au cours d'un traitement par anti-TNF. Annales de Dermatologie et de Vénéréologie, pp.811-815, 2009.
DOI : 10.1016/j.annder.2009.09.008

J. Galloway, K. Hyrich, L. Mercer, W. Dixon, B. Fu et al., Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly, Rheumatology, vol.50, issue.1, pp.124-155, 2011.
DOI : 10.1093/rheumatology/keq242

J. Curtis, N. Patkar, A. Xie, C. Martin, J. Allison et al., Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists

W. Dixon, D. Symmons, M. Lunt, K. Watson, K. Hyrich et al., Serious infection following anti???tumor necrosis factor ?? therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies, Arthritis & Rheumatism, vol.54, issue.9, pp.2896-904, 2007.
DOI : 10.1002/art.22808

A. Alonso-ruiz, J. Pijoan, E. Ansuategui, A. Urkaregi, M. Calabozo et al., Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety, BMC Musculoskeletal Disorders, vol.36, issue.42, p.52, 2008.
DOI : 10.1080/03009740701607067

J. Askling, C. Fored, L. Brandt, E. Baecklund, L. Bertilsson et al., Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists, Annals of the Rheumatic Diseases, vol.66, issue.10, pp.1339-1383, 2007.
DOI : 10.1136/ard.2006.062760

R. Westhovens, D. Yocum, J. Han, A. Berman, I. Strusberg et al., The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial, Arthritis & Rheumatism, vol.46, issue.4, pp.1075-86, 2006.
DOI : 10.1002/art.21734

A. Collamer, K. Guerrero, J. Henning, and D. Battafarano, Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action, Arthritis & Rheumatism, vol.44, issue.7
DOI : 10.1002/art.23835

U. Wollina, G. Hansel, A. Koch, J. Schönlebe, E. Köstler et al., Tumor Necrosis Factor-?? Inhibitor-Induced Psoriasis or Psoriasiform Exanthemata, American Journal of Clinical Dermatology, vol.56, issue.1, pp.1-14, 2008.
DOI : 10.2165/00128071-200809010-00001

M. Viguier, P. Richette, H. Bachelez, D. Wendling, and F. Aubin, Manifestations cutanées paradoxales des anti-TNF-alpha. Annales de Dermatologie et de Vénéréologie, pp.64-71, 2010.
DOI : 10.1016/j.annder.2009.10.004

J. Ko, A. Gottlieb, and J. Kerbleski, Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases, Journal of Dermatological Treatment, vol.174, issue.15, pp.100-108, 2009.
DOI : 10.1016/S0140-6736(02)08512-4

D. Wendling, J. Balblanc, D. Briançon, A. Brousse, A. Lohse et al., Onset or exacerbation of cutaneous psoriasis during TNF?? antagonist therapy, Joint Bone Spine, vol.75, issue.3, pp.315-323, 2008.
DOI : 10.1016/j.jbspin.2007.06.011

M. Harrison, W. Dixon, K. Watson, Y. King, R. Groves et al., Rates of newonset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for, Rheumatology Biologics Register

I. Sari, S. Akar, M. Birlik, B. Sis, F. Onen et al., Anti-tumor necrosis factor-alpha-induced psoriasis, J. Rheumatol, vol.33, issue.7, pp.1411-1415, 2006.

P. Richette, M. Viguier, H. Bachelez, and T. Bardin, Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?, J. Rheumatol, vol.34, issue.2, pp.438-447, 2007.

M. Ramos-casals, P. Brito-zerón, M. Soto, M. Cuadrado, and M. Khamashta, Autoimmune diseases induced by TNF-targeted therapies, Best Practice & Research Clinical Rheumatology, vol.22, issue.5, pp.847-61, 2008.
DOI : 10.1016/j.berh.2008.09.008

P. Voulgari, T. Markatseli, S. Exarchou, A. Zioga, and A. Drosos, Granuloma annulare induced by anti-tumour necrosis factor therapy, Annals of the Rheumatic Diseases, vol.67, issue.4, pp.567-70, 2008.
DOI : 10.1136/ard.2007.075663

URL : http://ard.bmj.com/cgi/content/short/67/4/567

S. Devos, N. Van-den-bossche, D. Vos, M. Naeyaert, and J. , Adverse Skin Reactions to Anti-TNF-Alpha Monoclonal Antibody Therapy, Dermatology, vol.206, issue.4, pp.388-90, 2003.
DOI : 10.1159/000069965

A. Deng, V. Harvey, B. Sina, D. Strobel, A. Badros et al., Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors (Abstract)

L. Bidre, E. Chaby, G. Martin, L. Perrussel, M. Sassolas et al., Pelade au cours d'un traitement par anti-TNF alpha : neuf cas. Annales de Dermatologie et de Vénéréologie, pp.285-93, 2011.

M. Battistella, J. Rivet, H. Bachelez, and F. Lioté, Lichen planus associated with etanercept, British Journal of Dermatology, vol.34, issue.0
DOI : 10.1111/j.1365-2133.2006.07478.x

. Dermatol, 174. CRI. Fiches pratiques. Utilisation de l'Abatacept. Revue du rhumatisme, pp.188-90, 2008.

M. Weinblatt, B. Combe, A. Covucci, R. Aranda, J. Becker et al., Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study, Arthritis & Rheumatism, vol.50, issue.9, pp.2807-2823, 2006.
DOI : 10.1002/art.22070

M. Khraishi, A. Russell, and W. Olszynski, Safety profile of abatacept in rheumatoid arthritis: A review, Clinical Therapeutics, vol.32, issue.11, pp.1855-70, 2010.
DOI : 10.1016/j.clinthera.2010.10.011

M. Schiff, Abatacept treatment for rheumatoid arthritis Rheumatology (Oxford) 2011 mars, pp.437-486

C. Salliot, M. Dougados, and L. Gossec, Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials, Annals of the Rheumatic Diseases, vol.68, issue.1
DOI : 10.1136/ard.2007.083188

S. Storage, H. Agrawal, and D. Furst, Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis, The Korean Journal of Internal Medicine, vol.25, issue.1, pp.1-17, 2010.
DOI : 10.3904/kjim.2010.25.1.1

O. Goldzweig and P. Hashkes, Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy, Drug Des Devel Ther, vol.5, pp.61-70, 2011.

G. Jones, A. Sebba, J. Gu, M. Lowenstein, A. Calvo et al., Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study, Annals of the Rheumatic Diseases, vol.69, issue.01, pp.88-96, 2010.
DOI : 10.1136/ard.2008.105197

A. De-la-commission-de-la-transparence-has and . Roactemra®, 183. Mohrbacher A. B cell non-Hodgkin's lymphoma: rituximab safety experience, Arthritis Res

P. Emery, R. Fleischmann, A. Filipowicz-sosnowska, J. Schechtman, L. Szczepanski et al., The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial, Arthritis & Rheumatism, vol.31, issue.5, pp.1390-400, 2006.
DOI : 10.1002/art.21778

R. Fleischmann, Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab, Seminars in Arthritis and Rheumatism, vol.38, issue.4, pp.265-80, 2009.
DOI : 10.1016/j.semarthrit.2008.01.001

. Ducasse, T. Vo-de-la, J. Pintado, M. Gordon, and M. Oyonarte, Lesiones cut??neas en una paciente con linfoma no Hodgkin, Enfermedades Infecciosas y Microbiolog??a Cl??nica, vol.25, issue.7, pp.489-90, 2007.
DOI : 10.1157/13108713

A. Bermúdez, F. Marco, E. Conde, E. Mazo, M. Recio et al., Fatal visceral varicellazoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma, Haematologica, vol.85, issue.8, pp.894-899, 2000.

D. Selleslag, A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B, Acta Biomed, vol.77, issue.2, pp.32-37, 2006.

S. Aksoy, H. Harputluoglu, S. Kilickap, D. Dede, O. Dizdar et al., Rituximab-related viral infections in lymphoma patients, Leukemia & Lymphoma, vol.23, issue.1, pp.1307-1319, 2007.
DOI : 10.1182/blood-2002-10-3162

. García-de-galdeano, D. Boyano, I. Smith-zubiaga, A. Alvarez, I. Cantón et al., Involvement of interleukin-6 in the biology and metastatic activity of B16F10 melanoma cells (Abstract). Eur. Cytokine Netw, pp.187-92, 1998.

R. Mouawad, O. Rixe, J. Meric, D. Khayat, and C. Soubrane, Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study, Cytokines, Cellular & Molecular Therapy, vol.7, issue.4, pp.151-157, 2002.
DOI : 10.1080/13684730210002328

G. Fogarty, M. Bayne, P. Bedford, R. Bond, and G. Kannourakis, Three Cases of Activation of Cutaneous Squamous-cell Carcinoma During Treatment with Prolonged Administration of Rituximab, Clinical Oncology, vol.18, issue.2, pp.155-161
DOI : 10.1016/j.clon.2005.11.015

M. Wirges, F. Saporito, and J. Smith, Rapid growth of Merkel cell carcinoma after treatment with rituximab, J Drugs Dermatol, vol.5, issue.2, pp.180-181, 2006.

K. Clifford and M. Demierre, Progression of classic Kaposi's sarcoma with rituximab, Journal of the American Academy of Dermatology, vol.53, issue.1
DOI : 10.1016/j.jaad.2004.12.048

J. Sibilia and R. Westhovens, Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis (Abstract), Clin. Exp. Rheumatol, vol.25, issue.5, pp.46-56, 2007.

J. Kremer, M. Dougados, P. Emery, P. Durez, J. Sibilia et al., Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial, Arthritis & Rheumatism, vol.20, issue.8, pp.2263-71, 2005.
DOI : 10.1002/art.21201

M. Weinblatt, B. Combe, A. Covucci, R. Aranda, J. Becker et al., Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study, Arthritis & Rheumatism, vol.50, issue.9, pp.2807-2823, 2006.
DOI : 10.1002/art.22070

M. Kim, H. Kim, H. Kim, and Y. Park, Rituximab-induced vasculitis: A case report and review of the medical published work, The Journal of Dermatology, vol.94, issue.5, pp.284-291, 2009.
DOI : 10.1111/j.1346-8138.2009.00639.x

S. Lowndes, A. Darby, G. Mead, and A. Lister, Stevens-Johnson syndrome after treatment with rituximab, Annals of Oncology, vol.13, issue.12, pp.1948-50, 2002.
DOI : 10.1093/annonc/mdf350